

ADMA BIOLOGICS, INC.
Form 8-K
March 21, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 15, 2013

ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-52120
(Commission
File Number)

56-2590442
(IRS Employer
Identification No.)

65 Commerce Way Hackensack, New Jersey
(Address of principal executive offices)

07601
(Zip Code)

Registrant's telephone number, including area code: (201) 478-5552

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet
2.03 Arrangement of a Registrant.

On March 15, 2013, ADMA Biologics, Inc. (the “Company”) borrowed an additional \$1 million under its Loan and Security Agreement, dated December 21, 2012, with Hercules Technology Growth Capital, Inc. upon reaching its first milestone under the agreement.

The remaining information required to be disclosed under this Item is incorporated herein by reference to “Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources - Hercules Loan and Security Agreement” in the Company’s annual report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission on March 6, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 21, 2013

ADMA Biologics, Inc.

By: /s/ Brian Lenz

Name: Brian Lenz

Title: Chief Financial Officer